Efficacy News and Research

RSS
PSST training helps mothers to cope with stress associated with child's disease

PSST training helps mothers to cope with stress associated with child's disease

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Techulon signs license with Virginia Tech Intellectual Properties to market DNA delivery platform

Researcher develops workshop method to help children deal with PTSD

Researcher develops workshop method to help children deal with PTSD

Paragon Bioservices awarded contract to assist USAMRIID in vaccine development efforts

Paragon Bioservices awarded contract to assist USAMRIID in vaccine development efforts

Scientists discover new cell that may limit inflammation in CNS

Scientists discover new cell that may limit inflammation in CNS

New review outlines Bionovo's platform of estrogen receptor modulators for menopausal conditions

New review outlines Bionovo's platform of estrogen receptor modulators for menopausal conditions

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Regulus present advancements in microRNA platform at Oligonucleotide Therapeutics Society meeting

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

Zyvox achieves higher clinical success rate than vancomycin in MRSA nosocomial pneumonia study

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

European FP7 research project to develop environment-friendly pest control products

European FP7 research project to develop environment-friendly pest control products

Study investigates efficacy of blood analysis with cognitive testing for early diagnosis of AD

Study investigates efficacy of blood analysis with cognitive testing for early diagnosis of AD

MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress

MAP Pharmaceuticals to present nine analyses on LEVADEX for migraine therapy at 2010 EHMTIC congress

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Kinemed updates translational biomarkers strategy at 2010 Conference in Boston

Kinemed updates translational biomarkers strategy at 2010 Conference in Boston

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.